Plasma sex steroid and gonadotropin levels in control and silastic vaginal medroxyprogesterone acetate-impregnated ring cycles.
The concentrations of sex steroid hormones in plasma were determined daily in 14 young adult women, during both a control cycle and a treatment cycle. During the latter a Silastic ring into which 100 or 200 mg of medroxyprogesterone acetate (Provera) had been incorporated was worn intravaginally. During the treatment cycles, plasma levels of estradiol, progesterone, and 17-hydroxyprogesterone remained within the range observed during the early follicular phase. Testosterone and androstenedione levels did not show any cyclic variation during the treatment cycle; however, the mean levels were decreased by about 25% compared with the over-all plasma levels of the control cycle, whereas dehydroepiandrosterone levels were decreased by about 15%. It is concluded that these Provera-containing Silastic intravaginal rings inhibit ovulation and decrease androgen secretion by the ovaries significantly.
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006062:Gonadotropins / Q000097:blood*; D006801:Humans; D006908:Hydroxyprogesterones / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D012826:Silicone Elastomers; D013739:Testosterone / Q000097:blood; D014621:Vagina
D003271:Contraceptive Agents, Female; D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D006908:Hydroxyprogesterones; D012826:Silicone Elastomers; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone